Release Date: March 8, 2023
Expiration Date: March 8, 2024
Activity Overview
The therapeutic armamentarium for management of renal cell carcinoma (RCC) has quickly expanded over the past decade with the introduction of novel immunotherapy- and targeted therapy–based approaches. While this evolution of practice offers unprecedented opportunities for patient benefit, it also places substantial strain on busy clinicians to remain updated.
This on-demand symposium webcast is designed to provide clinicians with current best practices for selection and delivery of therapy across the disease continuum for RCC. Through didactic presentations and case-based discussions, participants will be given the opportunity to learn about key principles for optimal treatment selection for individual patients.
This educational activity is an archive of the live hybrid symposium held on February 17, 2023.
Target Audience
This educational program is directed toward oncologists, urologists, and other allied health care professionals who treat or manage RCC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the mechanistic rationale for evaluating targeted therapies, immunotherapies, and combinations to manage RCC
- Assess the implications of recent trial data on novel therapies and combinations in the context of evolving treatment paradigms for high-risk, advanced/metastatic, and early-stage RCC
- Determine effective strategies for the identification and management of treatment-related toxicities among patients who receive care for RCC
- Devise personalized care plans for RCC by incorporating methods to stratify risk, clinical trial evidence, and patient- and tumor-specific characteristics
Toni Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Calithera, Celldex Therapeutics, Exelixis, Foundation Medicine, GSK, Merck, Novartis, Peloton, Pfizer, Roche, Takeda, TRACON Pharmaceuticals; Consultant: Alexion, Alligent, Analysis Group, AstraZeneca, Bayer, Bristol Myers Squibb, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, Exelixis, Foundation Medicine, GSK, Genentech, Ipsen, Merck, NCCN, Novartis, Peloton, Pfizer, Prometheus Laboratories, Roche, Sanofi/Aventis, UpToDate.
Shuchi Gulati, MD, MSc
Assistant Professor of Medicine
Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosures Consultant: AVEO Oncology, EMD Serono.
Sumanta Pal, MD, FASCO
Professor of Medical Oncology & Therapeutics Research
Co-director
Kidney Cancer Program
City of Hope
Duarte, CA
Disclosures Consultant: Astellas Pharma, Bristol Myers Squibb, Exelixis, GSK, Ipsen, Medivation, Novartis, and Pfizer.
Thomas Powles, MBBS, MRCP, MD
Clinical Professor of Genitourinary Oncology (HCC)
Experimental Cancer Medicine Centre
Barts Cancer Institute
Barts and The London School of Medicine and Dentistry
London, England
Disclosures: Grant/Research Support: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Seagen; Consultant: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Mashup, Merck, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Seagen.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.